197 related articles for article (PubMed ID: 35471657)
1. Coming of Age: Human Genomics and the Cancer-Immune Set Point.
Hammer C; Mellman I
Cancer Immunol Res; 2022 Jun; 10(6):674-679. PubMed ID: 35471657
[TBL] [Abstract][Full Text] [Related]
2. Germline Genetics in Immuno-oncology: From Genome-Wide to Targeted Biomarker Strategies.
Kirchhoff T; Ferguson R
Methods Mol Biol; 2020; 2055():93-117. PubMed ID: 31502148
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic implications of germline genetic findings in cancer.
Thavaneswaran S; Rath E; Tucker K; Joshua AM; Hess D; Pinese M; Ballinger ML; Thomas DM
Nat Rev Clin Oncol; 2019 Jun; 16(6):386-396. PubMed ID: 30783251
[TBL] [Abstract][Full Text] [Related]
4. Germline Variants That Affect Tumor Progression.
Chatrath A; Ratan A; Dutta A
Trends Genet; 2021 May; 37(5):433-443. PubMed ID: 33203571
[TBL] [Abstract][Full Text] [Related]
5. Substantial batch effects in TCGA exome sequences undermine pan-cancer analysis of germline variants.
Rasnic R; Brandes N; Zuk O; Linial M
BMC Cancer; 2019 Aug; 19(1):783. PubMed ID: 31391007
[TBL] [Abstract][Full Text] [Related]
6. Personalized Immuno-Oncology.
Jain KK
Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
[TBL] [Abstract][Full Text] [Related]
7. Immunogenomics in personalized cancer treatments.
Kiyotani K; Toyoshima Y; Nakamura Y
J Hum Genet; 2021 Sep; 66(9):901-907. PubMed ID: 34193979
[TBL] [Abstract][Full Text] [Related]
8. Functional genomics: paving the way for more successful cancer immunotherapy.
Ajina R; Zamalin D; Weiner LM
Brief Funct Genomics; 2019 Mar; 18(2):86-98. PubMed ID: 29762641
[TBL] [Abstract][Full Text] [Related]
9. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.
Schrader KA; Cheng DT; Joseph V; Prasad M; Walsh M; Zehir A; Ni A; Thomas T; Benayed R; Ashraf A; Lincoln A; Arcila M; Stadler Z; Solit D; Hyman DM; Zhang L; Klimstra D; Ladanyi M; Offit K; Berger M; Robson M
JAMA Oncol; 2016 Jan; 2(1):104-11. PubMed ID: 26556299
[TBL] [Abstract][Full Text] [Related]
10. Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health.
Cheng F; Liang H; Butte AJ; Eng C; Nussinov R
Pharmacol Rev; 2019 Jan; 71(1):1-19. PubMed ID: 30545954
[TBL] [Abstract][Full Text] [Related]
11. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.
Mandal R; Chan TA
Cancer Discov; 2016 Jul; 6(7):703-13. PubMed ID: 27107038
[TBL] [Abstract][Full Text] [Related]
12. Integrating germline and somatic variation information using genomic data for the discovery of biomarkers in prostate cancer.
Mamidi TKK; Wu J; Hicks C
BMC Cancer; 2019 Mar; 19(1):229. PubMed ID: 30871495
[TBL] [Abstract][Full Text] [Related]
13. Cancer Treatment in the Genomic Era.
Doherty GJ; Petruzzelli M; Beddowes E; Ahmad SS; Caldas C; Gilbertson RJ
Annu Rev Biochem; 2019 Jun; 88():247-280. PubMed ID: 30901264
[TBL] [Abstract][Full Text] [Related]
14. The emerging significance of secondary germline testing in cancer genomics.
Mandelker D; Zhang L
J Pathol; 2018 Apr; 244(5):610-615. PubMed ID: 29293272
[TBL] [Abstract][Full Text] [Related]
15. Precision diagnostics in cancer: Predict, prevent, and personalize.
Crabtree JS; Miele L
Prog Mol Biol Transl Sci; 2022; 190(1):39-56. PubMed ID: 36008001
[TBL] [Abstract][Full Text] [Related]
16. Approaches to integrating germline and tumor genomic data in cancer research.
Feigelson HS; Goddard KA; Hollombe C; Tingle SR; Gillanders EM; Mechanic LE; Nelson SA
Carcinogenesis; 2014 Oct; 35(10):2157-63. PubMed ID: 25115441
[TBL] [Abstract][Full Text] [Related]
17. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
[TBL] [Abstract][Full Text] [Related]
18. [Genomics medicine and oncology].
Michielin O; Coukos G
Praxis (Bern 1994); 2014 May; 103(10):591-6. PubMed ID: 24800772
[TBL] [Abstract][Full Text] [Related]
19. From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards.
Perera-Bel J; Hutter B; Heining C; Bleckmann A; Fröhlich M; Fröhling S; Glimm H; Brors B; Beißbarth T
Genome Med; 2018 Mar; 10(1):18. PubMed ID: 29544535
[TBL] [Abstract][Full Text] [Related]
20. Discrepancies between tumor genomic profiling and germline genetic testing.
Pauley K; Koptiuch C; Greenberg S; Kohlmann W; Jeter J; Colonna S; Werner T; Kinsey C; Gilcrease G; Weis J; Whisenant J; Florou V; Garrido-Laguna I
ESMO Open; 2022 Aug; 7(4):100526. PubMed ID: 35780590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
